– NACD Directorship 100 Recognizes the Most Influential Corporate Directors and Governance Experts –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates.

“We have been honored to have Kevin serve as the Lead Independent Director on the Gilead Board since 2020, and as a Board member since 2009. In recent years, the company has undergone a significant transformation and Kevin’s leadership has been invaluable during this time,” said Daniel O’Day, Chairman and CEO, Gilead Sciences. “With Kevin’s strong integrity, his commitment to health equity and exemplary leadership skills, I believe this recognition is very well-deserved.”

The 2023 NACD Directorship 100 recognizes leading corporate directors and governance advocates in several categories, including attorneys, audit and risk professionals, board advisors, compensation experts, governance advisors, investors, media, policy advisors, recruiters, regulators and rule makers.

The complete list of the 2023 NACD Directorship 100 is available at https://directorship100.nacdonline.org/honorees/2023.

“Exemplifying board leadership is a top priority for our organization, and this year's peer-nominated Directorship 100 honorees demonstrate their excellence in governance,” said NACD president and CEO Peter Gleason. “The accomplishments and integrity of this year’s director honorees are inspiring, and we look forward to celebrating these individuals at our annual gala in New York.”

An independent selection committee reviews the nominees’ history of advancing board performance and leading corporate governance practices in accordance with established NACD principles. The principles form a framework that encourages corporate governance excellence in areas that include risk oversight, corporate strategy, compensation, and transparency.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

About NACD

The National Association of Corporate Directors (NACD) is the premier membership organization for board directors who want to expand their knowledge, grow their network, and maximize their potential.

As the unmatched authority in corporate governance, NACD sets the standards of excellence through its research and community-driven director education, programming, and publications. Directors trust NACD to arm them with the relevant insights to make high-quality decisions on the most pressing and strategic issues facing their businesses today.

NACD also prepares leaders to meet tomorrow's biggest challenges. The NACD Directorship Certification® is the leading director credential in the United States. It sets a new standard for director education, positions directors to meet boardroom challenges, and includes an ongoing education requirement that prepares directors for what is next.

With an ever-expanding community of more than 23,000 members and a nationwide chapter network, our impact is both local and global. NACD members are driven by a common purpose: to be trusted catalysts of economic opportunity and positive change—in business and in the communities we serve.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231002292467/en/